A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
NCT06844383
This study is recruiting at 8 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate or darolutamide
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer (Adenocarcinoma)
- mCRPC (Metastatic Castration-resistant Prostate Cancer)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Prostate Cancer Clinical Trials Consortium
- Last updated on ClinicalTrials.gov
- August 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- City of Hope · Duarte, CA
- UCSD Moores Cancer Center · La Jolla, CA
Massachusetts · 1
- Dana Farber Cancer Institute · Boston, MA
Minnesota · 1
- Masonic Cancer Center · Minneapolis, MN
New York · 1
- Memorial Sloan Kettering Cancer Center · New York, NY
Pennsylvania · 1
- Abramson Cancer Center of the University of Pennsylvania, Hospital of the University of Pennsylvania · Philadelphia, PA
Washington · 1
- Fred Hutchinson Cancer Center · Seattle, WA
Wisconsin · 1
- University of Wisconsin Carbone Cancer Center-Madison · Madison, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.